Xiaohongshu and Meituan Launch "Red-Mei Plan" Following "Red-Cat" and "Red-Jing" Partnerships

Deep News
01/13

Xiaohongshu has reportedly reached an agreement with Meituan on the "Red-Mei Plan," initially opening up Meituan's medicine-buying business line, allowing merchants on the Meituan platform to place ad notes on Xiaohongshu with direct links for "seamless shopping inspiration." This marks the first participation of an on-demand retail platform, following the "Red-Cat Plan" and "Red-Jing Plan" signed between Xiaohongshu and e-commerce platforms like Taobao Tmall and JD.com in May 2025.

Products such as Kuaike, Xiaokuihua, and Fenbid have become the first pharmaceutical brands to trial the "seamless shopping inspiration" feature under the Red-Mei Plan. During the peak winter season for medicine purchases, this feature has driven an average 42% increase in brand search volume within Xiaohongshu, enabling one-click redirection to Meituan's medicine-buying service to complete transactions, with order costs dropping over 33% compared to the industry average.

Public information indicates that Meituan currently supports on-demand retail services in nearly 3,000 cities, counties, and districts nationwide, with over 250,000 pharmacies on its platform, including more than 15,000 24-hour pharmacies.

Launched officially by Xiaohongshu in September 2025, the "seamless shopping inspiration" feature addresses the challenging "last mile" in the brand inspiration process. Brands have discovered that combining "seamless shopping inspiration" with inspirational ad placements boosts in-store efficiency by 76% compared to using either tool alone.

Public materials show that during the 2025 Double 11 shopping festival, the number of brands adopting the "seamless shopping inspiration" feature doubled compared to the 618 mid-year event, with over 1,000 products achieving million-level transactions on platforms like Tmall and JD.com through Xiaohongshu's inspiration-driven redirects.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10